VP45.31: Prevalence of SARS‐CoV2 in asymptomatic patients

Abstract

Virtual poster abstracts intervention will consist of low doses of hydroxychloroquine (Plaquenil) 200mg tablets every 24 hours for 15 days, with a follow-up of 21 days after inclusion in the study. Inclusion criteria will consist of pregnant women older than 18 years of any gestational, with positive SARS-CoV2 infection by PCR testing, and a normal electrocardiogram. The primary outcome as the proportion of severe pneumonia (defined by the American Thoracic Society Criteria) will be evaluated between the control group and the experimental group using relative risk (RR) and absolute risk increase (ARI) in the established period of time plus their respective 95% confidence intervals. (95% CI). Results: We hypothesize that pregnant women with non-severe COVID-19 taking hdroxychloroquine will have an 8% lower risk for progression to severe pneumonia compared to those taking placebo. Conclusions: This study will provide crucial information on the effectiveness of hydroxychloroquine for the prevention of severe COVID-19 pneumonia, and if proven effective, the information of this study will help save the lives of these pregnant women by preventing a severe form of the disease.